The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.
This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.
This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.
EXECUTIVE SUMMARY i. Clinical Applications for Organ Regeneration a. Bone Marrow Disease b. Diabetes c. Intestinal Disorders d. Kidney Disease e. Liver Disease ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Technologies Under Development for Organ Regeneration a. Bone Marrow Regeneration Technologies b. Intestine Regeneration Technologies c. Kidney Regeneration Technologies d. Liver Regeneration Technologies e. Pancreas Regeneration Technologies f. Bioartificial Organ Technologies iv. Market Analysis v. Methodology Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION 1.1 Disease Incidence 1.1.1 Bone Marrow Disease 22.214.171.124 Aplastic Anemia 126.96.36.199 Leukemia and Lymphoma 1.1.2 Diabetes 1.1.3 Intestinal Disorders 188.8.131.52 Intestinal Pseudo-Obstruction 184.108.40.206 Microvillus Inclusion Disease 220.127.116.11 Short Bowel Syndrome 1.1.4 Kidney Disease 1.1.5 Liver Disease 1.2 Existing Therapies 1.2.1 Ex Vivo Systems 18.104.22.168 Kidney Dialysis Systems 1.2.2 Organ Transplantation 22.214.171.124 Bone Marrow Transplantation 126.96.36.199 Kidney Transplantation 188.8.131.52 Liver Transplantation 184.108.40.206.1 Split Cadaveric Livers 220.127.116.11.2 Liver Segments from Living Donors 18.104.22.168 Pancreas Transplantation 22.214.171.124 Intestinal Transplantation Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 126.96.36.199 Collagen 188.8.131.52 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 184.108.40.206 Deoxyribonucleic Acid Transfection Vectors 220.127.116.11 Genetically Manipulated Cells 18.104.22.168 Three-Dimensional Polymer Technology 22.214.171.124 Transgenics 126.96.36.199 Fibroblasts 188.8.131.52 Immortalized Neural Stem Cells 184.108.40.206 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 220.127.116.11 Flatbed Perfusion Systems 18.104.22.168 Hollow Fiber Bioreactor Systems 22.214.171.124 Cell Suspension Systems 126.96.36.199 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS 3.1 Emerging Technologies and Products 3.1.1 Genes 3.1.2 Scaffolds 3.1.3 Stem Cells 3.1.4 Xenotransplants 3.1.5 Bone Marrow 188.8.131.52 Gamida Cell 184.108.40.206 Osiris Therapeutics 220.127.116.11 SituGen 18.104.22.168 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer 3.1.6 Intestine 3.1.7 Kidney 22.214.171.124 Tengion 3.1.8 Liver 126.96.36.199 Cytonet 188.8.131.52 StemCells 184.108.40.206 Vesta Therapeutics 3.1.9 Pancreas 220.127.116.11 BioTime 18.104.22.168 Cerco Medical 22.214.171.124 Geron 126.96.36.199 Juvenile Diabetes Research Foundation 188.8.131.52 Osiris Therapeutics 184.108.40.206 ViaCyte 220.127.116.11 StemCells 18.104.22.168 TheraCyte 22.214.171.124 Transition Therapeutics 126.96.36.199 ViaCord/PerkinElmer 188.8.131.52 Vitro Biopharma/Vitro Diagnostics 3.2 Artificial Organ Technologies 3.2.1 Bioartificial Kidney 3.2.2 Bioartificial Liver 184.108.40.206 Excorp Medical 220.127.116.11 Gambro 18.104.22.168 HepaLife Technologies 22.214.171.124 Hep-Art Medical Devices 126.96.36.199 Hybrid Organ 188.8.131.52 Vital Therapies 184.108.40.206 Xenogenics/MultiCell Technologies 3.2.3 Artificial Pancreas 220.127.116.11 Juvenile Diabetes Research Foundation 18.104.22.168 Medtronic 3.3 Market Analysis 3.3.1 Market Drivers 3.3.2 Market Limiters 3.4 Competitors Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products Exhibit 3-4: Medtronic's STAR 3 Study Results Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019 4. COMPANY PROFILES 4.1 BioTime, Inc. 4.2 Cerco Medical LLC 4.3 Cytonet GmbH & Co. KG 4.4 Geron Corporation 4.5 Osiris Therapeutics, Inc. 4.6 PerkinElmer, Inc. 4.7 StemCells, Inc. 4.8 Tengion, Inc. 4.9 Vesta Therapeutics, Inc. 4.10 ViaCyte, Inc. APPENDIX: COMPANY LISTING